Delayed rises in serum S100B levels and adverse neurological outcome in infants and children undergoing cardiopulmonary bypass

Lardner, David; Davidson, Andrew R.; McKenzie, Ian; Cochrane, Andrew

doi:10.1111/j.1460-9592.2004.01230.x

Cited by 30 publications

(29 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Serum S100b can detect early brain injury, 11,29 change in response to secondary brain insults 30 , and predict outcome after various adult and pediatric CNS injuries 18,29,31–34 . Berger et al found that initial and peak serum S100b concentrations were increased in children with hypoxic-ischemic injury and traumatic brain injury (TBI) but children with TBI peaked earlier (6 vs. 9 hours) 20 .…”

Section: Discussionmentioning

confidence: 99%

Serum Biomarkers of Brain Injury to Classify Outcome After Pediatric Cardiac Arrest*

Fink

Berger

Clark

et al. 2014

Critical Care Medicine

View full text Add to dashboard Cite

Objective Morbidity and mortality in children with cardiac arrest (CA) largely result from neurologic injury. Serum biomarkers of brain injury can potentially measure injury to neurons (neuron specific enolase [NSE]), astrocytes (S100b), and axons (myelin basic protein [MBP]). We hypothesized that serum biomarkers can be used to predict outcome from pediatric CA. Design Prospective observational study. Setting Single tertiary pediatric hospital. Patients Forty-three children with cardiac arrest. Interventions None. Measurements and Main Results We measured serum NSE, S100b, and MBP on days 1–4 and 7 after CA. We recorded demographics, details of the CA and resuscitation, and Pediatric Cerebral Performance Category (PCPC) at hospital discharge and 6 months. We analyzed the association of biomarker levels at 24, 48, and 72 hours with good (PCPC 1–3) or poor (PCPC 4–6) outcome and mortality. Forty-three children (49% female; mean age of 5.9 ± 6.3 were enrolled and 17 (40%) died. Serum concentration at 24 hours for all 3 biomarkers predicted mortality (all p<0.05). Additionally, serum NSE and S100b concentrations were increased in the poor outcome vs. good outcome group and in subjects who died at all time points (all p<0.05). Receiver operator curves for serum S100b and NSE to predict good vs. poor outcome at 6 months was superior to clinical predictors. There was no association between serum biomarker concentrations and subject temperature. Conclusions Preliminary data show that serum S100b, NSE, and MBP may aid in outcome prediction of children surviving CA.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum Biomarkers of Brain Injury to Classify Outcome After Pediatric Cardiac Arrest*

Fink

Berger

Clark

et al. 2014

Critical Care Medicine

View full text Add to dashboard Cite

show abstract

“…Lardner et al reported data from 43 children undergoing surgery with CPB. (27) Neonates had elevated S100β levels preoperatively, and all patients had elevated levels immediately postbypass. There was no association between elevated S100β levels 24 hr after bypass and outcomes; however in the two patients with acute neurological injury and later developmental delay, the increase at 48 hr was significantly higher than the remaining patients without brain injury.…”

Section: Markers/surrogates For Neurological Injurymentioning

confidence: 89%

Neuroprotection in pediatric cardiac surgery: What is on the horizon?

Andropoulos

Brady

Easley

et al. 2010

Progress in Pediatric Cardiology

View full text Add to dashboard Cite

“…Increased S-100B levels correlate with the presence of brain infarction, and the extent of infarcted brain tissue. S-100B has been shown to predict survival, long-term outcome, degree of postoperative neurological deficit and intellectual impairment [131][132][133][134][135][136]. Moreover, Kanbak et al used serum S-100B in order to show that propofol offers no advantage over isoflurane anaesthesia for cerebral protection during cardio-pulmonary bypass [137].…”

Section: Stroke-cerebral Hypoxiamentioning

confidence: 99%

Serum S-100B Protein as A Biochemical Marker of Brain Injury: A Review of Current Concepts

Korfias

Stranjalis²,

Papadimitriou³

et al. 2006

CMC

View full text Add to dashboard Cite

S-100 protein, described initially by Moore, constitutes a large family of at least 20 proteins with calcium binding ability. It is found as homo- or hetero-dimers of two different subunits (A and B). Types S-100AB and S-100BB are described as S-100B protein and are shown to be highly specific for nervous tissue. It is present in the cytosol of glial and Schwann cells, and also in adipocytes and chondrocytes, although in very low concentrations in the latter two. The role of protein S-100B is not yet fully understood. It is suggested that it has intracellular and extracellular neurotropic as well as neurotoxic function. At nanomolar levels, S-100B stimulates neurite outgrowth and enhances survival of neurons. However, at micromolar levels it stimulates the expression of inflammatory cytokines and induces apoptosis. Recently, serum S-100B protein has been proved to be an attractive surrogate marker of primary severe brain injury and secondary insults. It can be measured in the arterial and venous serum; it is not affected by haemolysis and remains stable for several hours without the need for immediate analysis. Its short half-life makes measurements crucial in the emergency and intensive care settings. This review summarises published findings on S-100B regarding its role as a serum biochemical marker of brain injury, i.e., after severe, moderate or mild neuro-trauma, subarachnoid haemorrhage, thrombo-embolic stroke, cerebral ischaemia and brain tumours, as well as extracranial trauma, neurodegenerative and psychiatric disorders.

show abstract

Delayed rises in serum S100B levels and adverse neurological outcome in infants and children undergoing cardiopulmonary bypass

Cited by 30 publications

References 21 publications

Serum Biomarkers of Brain Injury to Classify Outcome After Pediatric Cardiac Arrest*

Serum Biomarkers of Brain Injury to Classify Outcome After Pediatric Cardiac Arrest*

Neuroprotection in pediatric cardiac surgery: What is on the horizon?

Serum S-100B Protein as A Biochemical Marker of Brain Injury: A Review of Current Concepts

Contact Info

Product

Resources

About